Skip to main content

Published locations for Brodalumab achieved primary endpoints for moderate to severe psoriasis at 52 weeks

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Brodalumab achieved primary endpoints for moderate to severe psoriasis at 52 weeks

User login

  • Reset your password
  • /content/brodalumab-achieved-primary-endpoints-moderate-severe-psoriasis-52-weeks
  • /edermatologynews/article/98091/psoriasis/brodalumab-achieved-primary-endpoints-moderate-severe
  • /rheumatologynews/article/98091/psoriasis/brodalumab-achieved-primary-endpoints-moderate-severe
  • /rheumatology/article/98091/psoriasis/brodalumab-achieved-primary-endpoints-moderate-severe-psoriasis
  • /dermatology/article/98091/psoriasis/brodalumab-achieved-primary-endpoints-moderate-severe-psoriasis
  • /rheumatology/psoriatic-arthritis-resource-center/article/98091/psoriasis/brodalumab-achieved-primary
  • /dermatology/psoriasiscollection/article/98091/psoriasis/brodalumab-achieved-primary-endpoints
  • /psoriatic-arthritis-icymi/article/98091/psoriasis/brodalumab-achieved-primary-endpoints-moderate